Rohit Loomba MD, Clinical/Scientific Advisor

Dr. Rohit Loomba is a leading expert in translational research and innovative clinical trial design in nonalcoholic fatty steatohepatitis (NASH) and fatty liver disease (NAFLD), a precursor to NASH.  He is a principle investigator for Gilead’s first-in-class ASK1 inhibitor program in NASH.


Dr. Loomba is the founding director of the University of California, San Diego NAFLD Translational Research Unit where his team is conducting cutting edge research in all aspects of NAFLD including non-invasive biomarkers, genetics, epidemiology, clinical trial design, imaging end-points, and integrated OMICs using microbiome, metabolome and lipidome. This integrated approach has led to several innovative applications. He follows one of the largest cohorts of well-characterized patients with NAFLD and applies evidence-based medicine to answer clinically relevant questions to improve management of patients with chronic liver disease.


He leads a multidisciplinary team of trainees, nurses, clinicians and scientists in conducting cutting edge translational research in liver disease. Dr. Loomba and his collaborators are leading a major effort into non-invasive biomarkers especially imaging modalities for assessment of fat, inflammation, cell injury and fibrosis in patients with chronic liver diseases, and developing therapies for the treatment of NASH and NASH related fibrosis.

Scott Friedman MD, Clinical/Scientific Advisor

Dean for Therapeutic Discovery 
Fishberg Professor of Medicine
Professor of Pharmacologic Sciences
Chief, Division of Liver Diseases

Icahn School of Medicine at Mount Sinai



Seal Rock Therapeutics - 500 Yale Ave N, Seattle, WA 98109, USA - -786.453.0593